Fankai K. Meng

No. 1095 Jiefang Avenue
Wuhan, 430030, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Long-term complete remission and minimal side effects after CD19/CD22 CAR-T cell cocktail therapy in a living donor with DLBCL: A rare case report.

Long-term complete remission and minimal side effects after CD19/CD22 CAR-T cell cocktail therapy in a living donor with DLBCL: A rare case report.

Journal: Cell transplantation

Published: June 03, 2026

Adenovirus-induced liver failure in adults following allogeneic hematopoietic stem cell transplantation: a report of two cases and literature review

Adenovirus-induced liver failure in adults following allogeneic hematopoietic stem cell transplantation: a report of two cases and literature review

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: February 09, 2026

Serglycin-ROS axis mediates synergistic lethality of PI3Kγ inhibition and Azacitidine in TP53-mutated AML.

Serglycin-ROS axis mediates synergistic lethality of PI3Kγ inhibition and Azacitidine in TP53-mutated AML.

Journal: BMC cancer

Published: November 12, 2025

Safety and Efficacy of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Therapy of Myelofibrosis.

Safety and Efficacy of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Therapy of Myelofibrosis.

Journal: Transplantation proceedings

Published: September 18, 2025

Expert Consensus on Cytomegalovirus Management in Recipients of CAR-T Cell and Bispecific Antibody Therapies.

Expert Consensus on Cytomegalovirus Management in Recipients of CAR-T Cell and Bispecific Antibody Therapies.

Journal: Journal of evidence-based medicine

Published: August 11, 2025

Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma.

Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma.

Journal: Signal transduction and targeted therapy

Published: July 28, 2025

Febrile neutropenia adversely affects chemomobilization outcomes in patients with multiple myeloma and increases risk for post-transplant infection in those with lymphoma: real-world multicenter data.

Febrile neutropenia adversely affects chemomobilization outcomes in patients with multiple myeloma and increases risk for post-transplant infection in those with lymphoma: real-world multicenter data.

Journal: Blood science (Baltimore, Md.)

Published: July 01, 2025

CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy.

CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy.

Journal: Cancer biology & medicine

Published: May 07, 2025

Comparison of Haploidentical-Hematopoietic Stem Cell Transplantation Using Modified Post-Transplantation Cyclophosphamide and Eltrombopag Combined With Immunosuppression for the Treatment of Severe Aplastic Anemia.

Comparison of Haploidentical-Hematopoietic Stem Cell Transplantation Using Modified Post-Transplantation Cyclophosphamide and Eltrombopag Combined With Immunosuppression for the Treatment of Severe Aplastic Anemia.

Journal: Transplantation and cellular therapy

Published: April 07, 2025

Comparative Analysis of T-Cell and Bone Marrow Chimerism for Relapse Prediction in Acute Leukaemia Post-Transplantation.

Comparative Analysis of T-Cell and Bone Marrow Chimerism for Relapse Prediction in Acute Leukaemia Post-Transplantation.

Journal: HLA

Published: January 24, 2025

Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysis.

Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysis.

Journal: Cancer treatment and research communications

Published: December 10, 2024

Long-term Therapy Outcomes of CD19/22 CAR T Cell Alone or with Autologous Stem Cell Transplantation for Relapsed/Refractory DLBCL.

Long-term Therapy Outcomes of CD19/22 CAR T Cell Alone or with Autologous Stem Cell Transplantation for Relapsed/Refractory DLBCL.

Journal: Blood cancer discovery

Published: November 18, 2024

Showing 1-12 of 61

Last Updated: 09/26/2026